Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1306 to 1320 of 1423 results for primary care

  1. Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

    NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus

    Medtech innovation briefing
    Published
    21 April 2015

  2. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued Reference number: GID-TA10321

    Technology appraisal guidance
    Discontinued

  3. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

    Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    8 February 2023
    View recommendations

    Sections for TA865

  5. Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more.

    Technology appraisal guidance
    Published
    25 November 2020
    View recommendations

    Sections for TA661

  6. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (TA772)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies.

    Technology appraisal guidance
    Published
    23 February 2022
    View recommendations

    Sections for TA772

  7. Palforzia for treating peanut allergy in children and young people (TA769)

    Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA769

  8. Pressure ulcer prevention: pressure ulcer risk assessment and prevention, including the use of pressure-relieving devices (beds, mattresses and overlays) for the prevention of pressure ulcers in primary and secondary care (CG7)

    This guidance has been updated and replaced by NICE guideline CG179.

    Withdrawn guideline

  9. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

    Technology appraisal guidance
    Published
    12 May 2025

    Sections for TA1062

  10. Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.

    Technology appraisal guidance
    Published
    23 June 2021
    View recommendations

    Sections for TA710

  11. Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    26 June 2019
    View recommendations

    Sections for TA587

  12. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    17 October 2023
    View recommendations

    Sections for TA927

  13. Interventions in a school setting:- Assess the clinical and cost effectiveness of an attachment-based intervention delivered in a school setting for children and young people on the edge of care, in the care system or adopted.

    delivered in a school setting for children and young people on the edge of care, in the care system or adopted. Any...

    Research recommendation
    Published
    11 December 2015

  14. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

    Medtech innovation briefing
    Published
    16 December 2014

  15. Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

    Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.

    Technology appraisal guidance
    Last updated
    1 January 2015
    View recommendations

    Sections for TA269